FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282939495> ?p ?o ?g. }

• W4282939495 endingPage "2594" @default.
• W4282939495 startingPage "2594" @default.
• W4282939495 abstract "Abstract DNA-damaging poisons and replicative stress commonly result in increased double-strand breaks (DSBs) in tumor cells. Non-homologous end joining (NHEJ), driven by the enzymatic function of DNA-PK, is one of the critical pathways employed to repair such DSBs. Inhibition of DNA-PK kinase activity impairs NHEJ, potentiates the activity of DNA-damaging agents, and inhibits survival of tumor cells incapable of repairing DSBs via other means, including homologous recombination (HR). We have developed an orally bioavailable, highly potent, and selective pharmacological inhibitor of DNA-PK activity, ZL-2201, for the treatment of cancer. ZL-2201 demonstrates enzymatic inhibition of DNA-PK in the single-digit nM range, with nearly 500-fold or greater selectivity against other phosphatidylinositol 3-kinase-related kinases (PIKKs). In addition, ZL-2201 showed high selectivity for DNA-PK kinase activity in a kinase panel screening study and a clean off-target profile with no appreciable inhibition against a panel of diverse, safety-relevant targets. We demonstrate that ZL-2201 effectively inhibits DNA-PK autophosphorylation and its downstream target phospho-RPA in multiple cell lines in a concentration- and time-dependent manner. DNA-PK has been shown previously to have synthetically lethal interactions with ATM. Therefore, we profiled the impact of ATM expression on the antiproliferative effects of ZL-2201. Cancer cell lines possessing defects in ATM displayed greater sensitivity to ZL-2201 compared to ATM-WT cancer cell lines. These observations were recapitulated in two ATM knockout isogenic cell lines. Moreover, ZL-2201 displayed minimal effects in a DNA-PK deficient model or in normal human and canine colon and kidney cell lines. Independent of ATM status, ZL-2201 showed strong synergy in vitro with topoisomerase II inhibitors. Following oral administration of ZL-2201 in vivo, ZL-2201 demonstrated dose-dependent and exposure-dependent antitumor activity against multiple models, with the greatest activity against ATM deficient human cancer xenografts. Antitumor activity correlated with duration of ZL-2201 exposure and level of target engagement. In addition, ZL-2201 significantly enhanced the activity of DNA-damaging agents in vivo, even in human cancer xenograft models with limited monotherapy antitumor activity for ZL-2201. The projected human PK properties, based on the ADME properties across species and PK properties in preclinical species of ZL-2201, suggest that ZL-2201 is suitable for oral administration. In conclusion, ZL-2201 demonstrates potent and selective inhibition of DNA-PK enzymatic activity, strong synergy with DNA damaging agents in vitro and in vivo, antitumor activity against multiple human xenograft models, and a favorable projected human PK profile. ZL-2201 is expected to enter clinical development in 2022. Citation Format: Shruti Lal, Bee-Chun Sun, Yuping Chen, Tom Huang, Neil Bhola, Vivian Morton, Kevin Chen, Shanghua Xia, Haoyu Zhang, Qiuping Ye, Petter Veiby, David I. Bellovin, Yuhua Ji. Discovery and characterization of ZL-2201, a potent, highly-selective, and orally bioavailable small-molecule DNA-PK inhibitor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2594." @default.
• W4282939495 created "2022-06-16" @default.
• W4282939495 creator A5002601658 @default.
• W4282939495 creator A5005711039 @default.
• W4282939495 creator A5008062526 @default.
• W4282939495 creator A5021225546 @default.
• W4282939495 creator A5025622672 @default.
• W4282939495 creator A5025961615 @default.
• W4282939495 creator A5027133629 @default.
• W4282939495 creator A5037183666 @default.
• W4282939495 creator A5045218258 @default.
• W4282939495 creator A5061037172 @default.
• W4282939495 creator A5066747947 @default.
• W4282939495 creator A5084676022 @default.
• W4282939495 creator A5084688051 @default.
• W4282939495 date "2022-06-15" @default.
• W4282939495 modified "2023-10-07" @default.
• W4282939495 title "Abstract 2594: Discovery and characterization of ZL-2201, a potent, highly-selective, and orally bioavailable small-molecule DNA-PK inhibitor" @default.
• W4282939495 doi "https://doi.org/10.1158/1538-7445.am2022-2594" @default.
• W4282939495 hasPublicationYear "2022" @default.
• W4282939495 type Work @default.
• W4282939495 citedByCount "1" @default.
• W4282939495 countsByYear W42829394952023 @default.
• W4282939495 crossrefType "journal-article" @default.
• W4282939495 hasAuthorship W4282939495A5002601658 @default.
• W4282939495 hasAuthorship W4282939495A5005711039 @default.
• W4282939495 hasAuthorship W4282939495A5008062526 @default.
• W4282939495 hasAuthorship W4282939495A5021225546 @default.
• W4282939495 hasAuthorship W4282939495A5025622672 @default.
• W4282939495 hasAuthorship W4282939495A5025961615 @default.
• W4282939495 hasAuthorship W4282939495A5027133629 @default.
• W4282939495 hasAuthorship W4282939495A5037183666 @default.
• W4282939495 hasAuthorship W4282939495A5045218258 @default.
• W4282939495 hasAuthorship W4282939495A5061037172 @default.
• W4282939495 hasAuthorship W4282939495A5066747947 @default.
• W4282939495 hasAuthorship W4282939495A5084676022 @default.
• W4282939495 hasAuthorship W4282939495A5084688051 @default.
• W4282939495 hasConcept C102744134 @default.
• W4282939495 hasConcept C121608353 @default.
• W4282939495 hasConcept C134935766 @default.
• W4282939495 hasConcept C143425029 @default.
• W4282939495 hasConcept C150109051 @default.
• W4282939495 hasConcept C153911025 @default.
• W4282939495 hasConcept C184235292 @default.
• W4282939495 hasConcept C185592680 @default.
• W4282939495 hasConcept C54355233 @default.
• W4282939495 hasConcept C552990157 @default.
• W4282939495 hasConcept C55493867 @default.
• W4282939495 hasConcept C68748289 @default.
• W4282939495 hasConcept C81885089 @default.
• W4282939495 hasConcept C86803240 @default.
• W4282939495 hasConcept C96232424 @default.
• W4282939495 hasConcept C97029542 @default.
• W4282939495 hasConceptScore W4282939495C102744134 @default.
• W4282939495 hasConceptScore W4282939495C121608353 @default.
• W4282939495 hasConceptScore W4282939495C134935766 @default.
• W4282939495 hasConceptScore W4282939495C143425029 @default.
• W4282939495 hasConceptScore W4282939495C150109051 @default.
• W4282939495 hasConceptScore W4282939495C153911025 @default.
• W4282939495 hasConceptScore W4282939495C184235292 @default.
• W4282939495 hasConceptScore W4282939495C185592680 @default.
• W4282939495 hasConceptScore W4282939495C54355233 @default.
• W4282939495 hasConceptScore W4282939495C552990157 @default.
• W4282939495 hasConceptScore W4282939495C55493867 @default.
• W4282939495 hasConceptScore W4282939495C68748289 @default.
• W4282939495 hasConceptScore W4282939495C81885089 @default.
• W4282939495 hasConceptScore W4282939495C86803240 @default.
• W4282939495 hasConceptScore W4282939495C96232424 @default.
• W4282939495 hasConceptScore W4282939495C97029542 @default.
• W4282939495 hasIssue "12_Supplement" @default.
• W4282939495 hasLocation W42829394951 @default.
• W4282939495 hasOpenAccess W4282939495 @default.
• W4282939495 hasPrimaryLocation W42829394951 @default.
• W4282939495 hasRelatedWork W1991644354 @default.
• W4282939495 hasRelatedWork W2004480716 @default.
• W4282939495 hasRelatedWork W2027189919 @default.
• W4282939495 hasRelatedWork W2033918102 @default.
• W4282939495 hasRelatedWork W2055890925 @default.
• W4282939495 hasRelatedWork W2108718931 @default.
• W4282939495 hasRelatedWork W2747101336 @default.
• W4282939495 hasRelatedWork W2760815521 @default.
• W4282939495 hasRelatedWork W3125757075 @default.
• W4282939495 hasRelatedWork W3185775632 @default.
• W4282939495 hasVolume "82" @default.
• W4282939495 isParatext "false" @default.
• W4282939495 isRetracted "false" @default.
• W4282939495 workType "article" @default.